| HOME >> MEDICINE >> TECHNOLOGY |
4.2.4 Serotonin-Norepinephrine Reuptake Inhibitors (SNRI) 44
4.2.5 Cymbalta (duloxetine hydrochloride) 44
4.2.6 Pristiq (desvenlafaxine succinate) 45
4.2.7 Symbyax (olanzapine and fluoxetine combination) 46
4.3 Key Takeaway 48
5 Depression Therapeutics - Pipeline Assessment 49
5.1 Overview 49
5.2 Strategic Pipeline Assessment 49
5.3 Depression Therapeutics Pipeline – Pipeline by Phases of Development 49
5.3.1 Depression Therapeutics – Phase III Pipeline 50
5.3.2 Depression Therapeutics – Phase II Pipeline 50
5.3.3 Depression Therapeutics – Phase I Pipeline 51
5.3.4 Depression Market – Pre-Clinical Pipeline 52
5.3.5 Technology Trends Analytic Framework 52
5.4 Depression Therapeutics Market –Pipeline by Mechanism of Action 56
5.5 Depression Therapeutics – Promising Drugs under Clinical Development 57
5.6 Molecule Profile for Promising Drugs Under Clinical Development 57
5.6.1 Lu AA21004 57
5.6.2 TC-5214 58
5.6.3 AGO178 (agomelatine) 59
5.7 Key Takeaway 60
6 Depression Therapeutics - Clinical Trials Mapping 61
6.1 Clinical Trials by Region/Country (US, EU5 and Japan) 61
6.2 Clinical Trials by Phase 62
6.3 Clinical Trials by Trial Status 63
6.4 Prominent Sponsors 64
6.5 Top Companies Participating in Depression Therapeutics Clinical Trials 66
7 Strategic Assessment 67
7.1 Key Events Impacting the Future Market 67
7.2 Depression Therapeutics: Implications for Future Market Competition 68
8 Depression Therapeutics: Future Players 69
8.1 Introduction 69
8.2 Company Profiles 69
8.2.1 Lundbeck A/S 69
8.2.2 Novartis AG 71
8.2.3 AstraZeneca PLC 72
8.2.4 Eli Lilly and Company 74
8.2.5 Targacept Inc. 75
9 Depression Therapeutics - Licensing and Partner
'/>"/>
| SOURCE Reportlinker Copyright©2010 PR Newswire. All rights reserved |